Floatz logo

Romiplostim

Thrombocytopenia

Cancer Institute and Hospital, Chinese Academy of Medical Sciencesprotein_peptidePhase 3Active
BB
70/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
57/ 100
Competitive Position
95/ 100

Competitive context

10 Active assets in the Thrombocytopenia cohort.

Asset / SponsorPhaseRating
Recombinant Human Thrombopoietin
Sun Yat-sen University
Phase 4BBB
sb-497115-gr
Institute of Hematology & Blood Diseases Hospital, China
Phase 4BB
FILGRASTIM
OHSU Knight Cancer Institute
Phase 2BB
Avatrombopag
Second Affiliated Hospital of Guangzhou Medical University
Phase 4BB
Cytosin-Arabinosid
OHSU Knight Cancer Institute
Phase 2BB

View all 50 →

Same molecule, other indications

Romiplostim is also rated in:

thrombocytopeniaDormant
BB
Indicative ·
65 / 100
View asset →
neoplasmDormant
BB
Indicative ·
65 / 100
View asset →
non-Hodgkin lymphomaDormant
B
Indicative ·
59 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →